Impact of Exercise/Sport on Well-being in Congenital Bleeding Disorders

Abstract

Physical activity provides many benefits in patients with congenital bleeding disorders. Patients with hemophilia are encouraged to participate in exercise and sports, especially those patients receiving prophylaxis. Several publications and guidelines have explored this issue in hemophilia patients, evaluating in particular the impact of physical activity on patients' well-being and quality of life. The other rare congenital bleeding disorders are less studied; they are heterogeneous in terms of clinical bleeding phenotype, incidence of hemarthrosis, and arthropathy. Furthermore, prophylaxis in these patients is less common than in hemophilia patients, which must be considered when choosing the type of physical and sporting activity. In this review, the authors have analyzed the literature focusing their attention on those rare coagulation disorders that may be complicated by arthropathy and the role of exercise and sports in this context.

Keywords

sport - exercise - arthropathy - joint bleeds - well-being - quality of life - rare inherited bleeding disorders

• References

• 1 Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev 2013; 27 (04) 179-184
• 2 Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008; 14 (Suppl. 03) 10-18
• 3 Franchini M. The modern treatment of haemophilia: a narrative review. Blood Transfus 2013; 11 (02) 178-182
• 4 Franchini M, Mannucci PM. The history of hemophilia. Semin Thromb Hemost 2014; 40 (05) 571-576
• 5 Tagliaferri A, Rivolta GF, Iorio A. , et al; Italian Association of Hemophilia Centers. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16 (03) 437-446
• 6 VON Mackensen S. Quality of life and sports activities in patients with haemophilia. Haemophilia 2007; 13 (Suppl. 02) 38-43
• 7 Limperg PF, Joosten MMH, Fijnvandraat K, Peters M, Grootenhuis MA, Haverman L. Male gender, school attendance and sports participation are positively associated with health-related quality of life in children and adolescents with congenital bleeding disorders. Haemophilia 2018; 24 (03) 395-404
• 8 Maffet M, Roton Jr J. Hemophilia in sports: a case report and prophylactic protocol. J Athl Train 2017; 52 (01) 65-70
• 9 Negrier C, Seuser A, Forsyth A. , et al. The benefits of exercise for patients with haemophilia and recommendations for safe and effective physical activity. Haemophilia 2013; 19 (04) 487-498
• 10 Howell C, Scott K, Patel DR. Sports participation recommendations for patients with bleeding disorders. Transl Pediatr 2017; 6 (03) 174-180
• 11 Hilberg T. Programmed sports therapy (PST) in people with haemophilia (PwH) “sports therapy model for rare diseases”. Orphanet J Rare Dis 2018; 13 (01) 38
• 12 Anderson A, Forsyth A. National Hemophilia Foundation. Playing it Safe. 2005. Available at: http://www.hemophilia.ca/files/PlayingItSafe.pdf . Accessed August 30, 2018
• 13 Cecchini C, Creighton K, Hann A. , et al. Canadian Hemophilia Society. Destination Fitness. 2nd ed. 2012 . Available at: http://www.hemophilia.ca/files/Destination%20fitness%20-%20FINAL.pdf . Accessed August 30, 2018
• 14 Zourikian N, Jarock C, Mulder K. Canadian Hemophilia Society. All About Hemophilia: A Guide for Families; Chapter 12: Physical Activity, Exercise and Sports. 2010. Available at: http://www.hemophilia.ca/files/Chapter%2012.pdf . Accessed August 30, 2018
• 15 Treatment Guidelines Working Group. World Federation of Hemophilia. Guidelines for the Management of Hemophilia. 2012 . Available at: https://www1.wfh.org/publication/files/pdf-1472.pdf . Accessed August 30, 2018
• 16 Franchini M, Favaloro EJ, Lippi G. Newer hemostatic agents. Semin Thromb Hemost 2015; 41 (07) 802-808
• 17 Wyseure T, Mosnier LO, von Drygalski A. Advances and challenges in hemophilic arthropathy. Semin Hematol 2016; 53 (01) 10-19
• 18 Acharya SS. Exploration of the pathogenesis of haemophilic joint arthropathy: understanding implications for optimal clinical management. Br J Haematol 2012; 156 (01) 13-23
• 19 Witkop M, Neff A, Buckner TW. , et al. Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Haemophilia 2017; 23 (04) 556-565
• 20 Sadler JE, Budde U, Eikenboom JC. , et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
• 21 Laffan MA, Lester W, O'Donnell JS. , et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (04) 453-465
• 22 van Galen KP, Mauser-Bunschoten EP, Leebeek FW. Hemophilic arthropathy in patients with von Willebrand disease. Blood Rev 2012; 26 (06) 261-266
• 23 van Galen KPM, Sanders YV, Vojinovic U. , et al; WiN Study Group. Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study. Haemophilia 2015; 21 (03) e185-e192
• 24 Acharya SS, Coughlin A, Dimichele DM. ; North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2 (02) 248-256
• 25 Bolton-Maggs PHB, Perry DJ, Chalmers EA. , et al. The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10 (05) 593-628
• 26 Girolami A, Vettore S, Ruzzon E, Marinis GB, Fabris F. Rare and unusual bleeding manifestations in congenital bleeding disorders: an annotated review. Clin Appl Thromb Hemost 2012; 18 (02) 121-127
• 27 Bairey O, Shaklai M, Inbal A. Haemarthrosis in patients with mild coagulation factor deficiency. Blood Coagul Fibrinolysis 1991; 2 (05) 669-671
• 28 Mannucci PM, Franchini M, Castaman G, Federici AB. ; Italian Association of Hemophilia Centers. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009; 7 (02) 117-126
• 29 Curnow J, Pasalic L, Favaloro EJ. Treatment of von Willebrand disease. Semin Thromb Hemost 2016; 42 (02) 133-146
• 30 Owens S, Baglin T. Recurrent haematomas of the thigh: a case of von Willebrand's disease presenting to a sports clinic. Br J Sports Med 2000; 34 (02) 122-123 , discussion 124
• 31 Kumar R, Stain AM, Hilliard P, Carcao M. Consequences of delayed therapy for sports-related bleeds in patients with mild-to-moderate haemophilia and type 3 von Willebrand's disease not on prophylaxis. Haemophilia 2013; 19 (04) e264-e267
• 32 Sood SL, Cuker A, Wang C. , et al; HTCN Study Investigators. Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A. Haemophilia 2013; 19 (04) 595-601
• 33 van Galen KPM, de Kleijn P, Foppen W. , et al; Win study group. Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. Haematologica 2017; 102 (09) 1486-1493
• 34 Federici AB. Prophylaxis in patients with von Willebrand disease: who, when, how?. J Thromb Haemost 2015; 13 (09) 1581-1584
• 35 Abshire TC, Federici AB, Alvárez MT. , et al; VWD PN. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia 2013; 19 (01) 76-81
• 36 Mannucci PM. Prophylaxis in congenital coagulation disorders: past, present and future. Blood Transfus 2008; 6 (Suppl. 02) s1-s3
• 37 Peyvandi F, Menegatti M, Palla R. Rare bleeding disorders: worldwide efforts for classification, diagnosis, and management. Semin Thromb Hemost 2013; 39 (06) 579-584
• 38 Rovenský J, Kosková E, Tauchmannová H, Bakosová J, Hurajl E, Hyrdelová E. Coxopathy in congenital afibrinogenemia. J Clin Rheumatol 2005; 11 (03) 182-184
• 39 Reidy K, Brand B, Jost B. Severe elbow arthropathy in a patient with congenital afibrinogenemia: a case report. J Bone Joint Surg Am 2010; 92 (02) 456-458
• 40 Castaman G, Linari S. Diagnosis and treatment of von Willebrand disease and rare bleeding disorders. J Clin Med 2017; 6 (04) E45
• 41 González-Boullosa R, Ocampo-Martínez R, Alarcón-Martín MJ, Suárez-Rodríguez M, Domínguez-Viguera L, González-Fajo G. The use of activated recombinant coagulation factor VII during haemarthroses and synovectomy in a patient with congenital severe factor V deficiency. Haemophilia 2005; 11 (02) 167-170
• 42 Mariani G, Testa MG, Di Paolantonio T, Molskov Bech R, Hedner U. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang 1999; 77 (03) 131-136
• 43 Tcheng WY, Donkin J, Konzal S, Wong WY. Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency. Haemophilia 2004; 10 (03) 295-298
• 44 Brenner B, Wiis J. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency. Hematology 2007; 12 (01) 55-62
• 45 Lapecorella M, Mariani G. ; International Registry on Congenital Factor VII Deficiency. Factor VII deficiency: defining the clinical picture and optimizing therapeutic options. Haemophilia 2008; 14 (06) 1170-1175
• 46 Herrmann FH, Auerswald G, Ruiz-Saez A. , et al; Greifswald Factor X Deficiency Study Group. Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia 2006; 12 (05) 479-489
• 47 Peyvandi F, Mannucci PM, Lak M. , et al. Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients. Br J Haematol 1998; 102 (02) 626-628
• 48 McMahon C, Smith J, Goonan C, Byrne M, Smith OP. The role of primary prophylactic factor replacement therapy in children with severe factor X deficiency. Br J Haematol 2002; 119 (03) 789-791
• 49 Souabni L, Meddeb N, Ajlani H, Romdhane NB, Sellami S. Hemarthrosis revealing congenital factor XI deficiency. J Bone Spine 2008; 334-349
• 50 Alavi SER, Jalalvand M, Assadollahi V, Tabibian S, Dorgalaleh A. Intracranial hemorrhage: a devastating outcome of congenital bleeding disorders-prevalence, diagnosis, and management, with a special focus on congenital factor XIII deficiency. Semin Thromb Hemost 2018; 44 (03) 267-275